Bill
Bill > H3551
summary
Introduced
01/22/2019
01/22/2019
In Committee
04/04/2019
04/04/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
191st General Court
Bill Summary
For legislation to promote transparency and cost control of pharmaceutical drug prices. Elder Affairs.
AI Summary
This bill aims to promote transparency and cost control of pharmaceutical drug prices. It requires the Massachusetts Health Policy Commission to develop a list of critical prescription drugs and compel drug manufacturers to report detailed information about the costs and pricing of these drugs, including production costs, research and development costs, marketing expenses, and net prices charged to various purchasers. The Commission will then analyze this data and identify drugs with excessively high prices that may jeopardize the state's healthcare cost growth benchmark. Additionally, the bill directs the Commission to conduct an analysis on the impact of discounts, rebates, and other cost-sharing reduction programs on healthcare costs and utilization in the state.
Committee Categories
Health and Social Services
Sponsors (11)
Diana Dizoglio (D),
Michelle DuBois (D),
Denise Garlick (D),
Colleen Garry (D),
Carmine Gentile (D),
Carlos González (D),
Stephen Hay (D),
David LeBoeuf (D),
Liz Miranda (D),
José Tosado (D),
Bud Williams (D),
Last Action
Reporting date extended to Thursday December 31, 2020, pending concurrence (on 06/22/2020)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://malegislature.gov/Bills/191/H3551 |
| Bill | https://malegislature.gov/Bills/191/H3551.pdf |
Loading...